Phaseline

Targets › ITGA2B

ITGA2B (Integrin alpha-IIb): drug programs, companies and trials

7 programs from 7 companies in 12 trials: 6 Phase 3, 3 Phase 2, 2 Phase 4, 1 Phase 1; Neurology, Cardiovascular, Other; next expected readout Dec 2026.

Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. (UniProt, P08514)

Open in Phaseline: the race on ITGA2B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing Anzhen HospitalTirofiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 4Acute Ischemic StrokeDec 2026
Second Affiliated Hospital of Soochow UniversityTirofiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 4Mild StrokeFeb 2027
Beijing Tiantan HospitalY-4 tablets
Integrin alpha-IIb/beta-3 inhibitor
PDE3A, ITGB3, ITGA2B, IL1R1Phase 3Ischemic Stroke, Acute; Aneurysmal Subarachnoid Hemorrhage; Acute Ischemic Stroke; Stroke Acute …Dec 2026
General Hospital of Shenyang Military RegionTirofiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3Stroke, IschemicSep 2027
Weifang Medical UniversityTirofiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3Stroke, AcuteFeb 2029
Second Affiliated Hospital of Guangxi Medical UniversityTirofiban Hydrochloride
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3Acute Ischemic Stroke–
CeleCor TherapeuticsZalunfiban
Integrin alpha-IIb/beta-3 inhibitor
ITGB3, ITGA2BPhase 3ST-elevation Myocardial Infarction (STEMI)–

Conditions

Acute Ischemic Stroke (3) Stroke Acute (2) ST-elevation Myocardial Infarction (STEMI) (1) Mild Stroke (1) Stroke, Ischemic (1) Ischemic Stroke, Acute (1) Aneurysmal Subarachnoid Hemorrhage (1) Healthy Adult Male and Female Volunteers (1) Stroke, Acute (1)

Modalities

small molecule (7)

Companies

CeleCor Therapeutics (1) Second Affiliated Hospital of Soochow University (1) General Hospital of Shenyang Military Region (1) Beijing Tiantan Hospital (1) Second Affiliated Hospital of Guangxi Medical University (1) Beijing Anzhen Hospital (1) Weifang Medical University (1)

Related targets

ITGB3 (7) PDE3A (1) IL1R1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.